Wellington Management Group LLP Sells 139,337 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Wellington Management Group LLP lowered its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 45.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 164,431 shares of the company's stock after selling 139,337 shares during the quarter. Wellington Management Group LLP owned 0.49% of TransMedics Group worth $10,252,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Arizona State Retirement System increased its stake in shares of TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock valued at $603,000 after buying an additional 184 shares during the period. Envestnet Portfolio Solutions Inc. increased its stake in shares of TransMedics Group by 7.2% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock valued at $294,000 after buying an additional 317 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group during the 4th quarter valued at approximately $31,000. Alliancebernstein L.P. raised its holdings in TransMedics Group by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after purchasing an additional 500 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its holdings in TransMedics Group by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company's stock worth $86,000 after purchasing an additional 504 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company's stock.

Insider Transactions at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director now directly owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Weill sold 732 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director now owns 12,134 shares in the company, valued at approximately $1,503,159.92. This represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,732 shares of company stock valued at $1,416,710 in the last quarter. 7.00% of the stock is currently owned by company insiders.

TransMedics Group Trading Up 2.6%

Shares of TMDX stock traded up $3.46 during trading hours on Friday, hitting $139.05. 783,703 shares of the company were exchanged, compared to its average volume of 1,360,051. The firm has a market cap of $4.70 billion, a P/E ratio of 147.93 and a beta of 2.10. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The company has a 50 day simple moving average of $101.54 and a two-hundred day simple moving average of $80.26.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.29 by $0.41. The company had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company's quarterly revenue was up 48.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 EPS. Equities analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Piper Sandler restated an "overweight" rating and set a $145.00 price target (up previously from $125.00) on shares of TransMedics Group in a report on Wednesday. Oppenheimer raised their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Needham & Company LLC restated a "hold" rating on shares of TransMedics Group in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and an average target price of $128.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.